Contributions of HypoHildur
User contributions·9 logged edits·page 1 of 1
Contributions by HypoHildur, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,388 edits includes activity predating the current log.
- 12:11, 25 Mar 2026 (diff | hist) Hunan Aslsen Technology 15,492 ±0 add the storage and handling guidance the organisation publishes
- 09:50, 4 Mar 2026 (diff | hist) Talk:Hypoglycaemia 400 +119 /* Mechanistic argument is not a guarantee */ new section
- 15:40, 9 Feb 2026 (diff | hist) Talk:Amylin receptor agonist 748 +184 /* Pramlintide uptake */ reply
- 17:45, 30 Dec 2025 (diff | hist) Weight regain after discontinuation 4,670 ±0 add the discontinuation rate attributable to this effect
- 07:23, 6 Dec 2025 (diff | hist) Shanghai ERP Biotechnology 9,648 +363 rm the comparison with another supplier; there is no common basis for it
- 10:58, 31 Mar 2025 (diff | hist) Contraindications of incretin therapy 4,296 +726 add the perioperative consideration with the society guidance it comes from
- 12:26, 14 Oct 2024 (diff | hist) Retention time 2,283 +256 add category for method validation
- 03:52, 19 Jul 2024 (diff | hist) Reconstitution of lyophilised peptides 2,071 ±0 expand §Mechanics
- 21:19, 15 Jul 2024 (diff | hist) Adverse effects of GLP-1 receptor agonists 2,045 ±0 m convert the adverse-event list to a table with both arms